Distinguished in Angiosarcoma

Dr. Alvaro Moreno

Hematology | Oncology
Mayo Clinic Hospital In Florida
4500 San Pablo Rd S, 
Jacksonville, FL 
Distinguished in Angiosarcoma
Mayo Clinic Hospital In Florida
4500 San Pablo Rd S, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alvaro Moreno is a Hematologist and an Oncologist in Jacksonville, Florida. Dr. Moreno is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

His clinical research consists of co-authoring 74 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Mayo Clinic Hospital In Florida
4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Biological
Study Drug: Therapeutic Estradiol
Study Phase: Phase 2
Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy
Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: FASN Inhibitor TVB-2640, Paclitaxel, Trastuzumab
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer (PROMISE)
Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer (PROMISE)
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Procedure, Other
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Drug
Study Drugs: Anastrozole, Letrozole
Study Phase: Phase 2
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drugs: GSK525762, Fulvestrant
Study Phase: Phase 1
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Binimetinib, Palbociclib, Trifluridine+Tipiracil Hydrochloride
Study Phase: Phase 2
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim
Study Phase: Phase 2
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Enrollment Status: Withdrawn
Publish Date: May 26, 2022
Intervention Type: Drug, Biological
Study Drugs: Abemaciclib, Trastuzumab Emtansine
Study Phase: Phase 2
A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy
A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy
Enrollment Status: Completed
Publish Date: June 01, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

74 Total Publications

Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer.
Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2024
Similar Doctors
Distinguished in Angiosarcoma
Dr. Unni C. Thomas
Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Unni C. Thomas
Hematology | Oncology

Cancer Specialists Of North Florida

5742 Booth Rd Ste A, 
Jacksonville, FL 
 (12.1 miles away)
904-739-7779
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Unni Thomas is a Hematologist and an Oncologist in Jacksonville, Florida. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Thomas is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. Daniel Kobrinski
Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Daniel Kobrinski
Hematology | Oncology

Cancer Specialists LLC

700 3rd St Ste 302, 
Neptune Beach, FL 
 (4.1 miles away)
904-997-3800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Kobrinski is a Hematologist and an Oncologist in Neptune Beach, Florida. Dr. Kobrinski is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Paget Disease of the Breast, and Breast Cancer. Dr. Kobrinski is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. Abraham Cheong
Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Abraham Cheong
Hematology | Oncology

Cancer Care Center (Camden Campus)

2040 Dan Proctor Dr Ste 180, 
Saint Marys, GA 
 (43.9 miles away)
912-466-5506
Languages Spoken:
English
See accepted insurances

Abraham Cheong is a Hematologist and an Oncologist in Saint Marys, Georgia. Dr. Cheong is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Lung Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moreno's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile